Ionis now has to prove it can sell
- Ionis is no longer mainly a research partner story. It now has direct U.S. launches to execute.
- Tryngolza won FDA approval for severe hypertriglyceridemia on June 24, 2026, turning a key regulatory risk into a launch risk.
- Management raised 2026 revenue guidance to $875 million to $900 million after faster olezarsen timing.
- The company still depends on partner royalties and R&D payments, so milestone timing can swing results.
- Finn's score is cautious because Ionis is spending heavily before its new products have proven durable sales.
Approval moved the burden to sales
The big change is that olezarsen, sold as Tryngolza, was approved by the FDA for severe hypertriglyceridemia on June 24, 2026. That was before the June 30 PDUFA date, which is the FDA's target decision date. The key question is no longer whether the FDA says yes. It is whether doctors prescribe it, insurers cover it, and patients stay on it.
The bull case is simple. Tryngolza ramps fast in the second half of 2026, Dawnzera keeps gaining in hereditary angioedema, and Ionis stays on track toward cash flow breakeven by 2028. If pelacarsen and WAINUA heart studies read out well, Ionis could also collect major milestones and build larger future royalty streams.
The bear case is also clear. Tringolza revenue could dip more than expected because of pricing changes made before the larger sHTG launch. Dawnzera could grow slowly in a crowded HAE market. SG&A, which includes sales and corporate costs, could rise faster than revenue as Ionis funds several launches at once.
The new tariff risk adds another open question. Ionis disclosed that a U.S. proclamation in April 2026 imposed tariffs of up to 100% on imported patented drugs and active pharmaceutical ingredients, with exceptions. The company is still evaluating the impact, so investors do not yet know how much this could raise supply costs.
From royalties to owned launches
Ionis develops antisense medicines. These are drugs designed to bind to RNA, which helps control how the body makes certain proteins. For years, Ionis made much of its money from partners, especially SPINRAZA royalties from Biogen and research payments from drug-company collaborations.
That model is changing. Ionis now sells its own drugs in the U.S., including Tryngolza for FCS and sHTG and Dawnzera for HAE. Direct sales can keep more value inside Ionis, but they also require sales teams, market access work, patient support, and more SG&A spending.
The company still uses partners where it needs reach or shared cost. AstraZeneca helps commercialize WAINUA, Biogen sells SPINRAZA and QALSODY, Sobi handles Tryngolza in many countries outside the U.S., Canada, and China, and Otsuka has Dawnzera rights in Europe and Asia-Pacific.
This mix can work if owned products grow faster than expenses. It can break if launches are slow, insurers limit access, partner milestones do not arrive on time, or tariffs lift manufacturing and supply costs.
The drugs that matter most
Tryngolza, olezarsen
Tryngolza began in FCS, a rare fat-processing disorder. The June 2026 FDA approval in severe hypertriglyceridemia opens a much larger market and is central to the growth case.
Dawnzera, donidalorsen
Dawnzera is Ionis's U.S. launch for preventing hereditary angioedema attacks. Management guided 2026 sales to $110 million to $120 million, so uptake is a key proof point.
SPINRAZA
SPINRAZA treats spinal muscular atrophy and is sold by Biogen. It remains the largest royalty source, although Q1 2026 SPINRAZA royalties were lower than the prior-year period.
WAINUA, eplontersen
WAINUA treats hereditary ATTR polyneuropathy and is partnered with AstraZeneca. The bigger future swing is the CARDIO-TTRansform study in ATTR cardiomyopathy.
Zilganersen
Zilganersen is under FDA review for Alexander disease, a rare and fatal brain disorder. Its PDUFA date is September 22, 2026, and management has guided to more than $100 million in peak sales potential.
Obudanersen, ION582
Obudanersen is in Phase 3 development for Angelman syndrome. Enrollment is expected to complete in 2026, with data expected in 2027.
QALSODY
QALSODY treats a genetic cause of ALS and is sold by Biogen in the U.S. and Europe. Ionis earns royalties rather than running the launch itself.
Q1 revenue mix
Ionis reports one operating segment, but Q1 2026 revenue is disclosed by stream. The mix is for the three months ended March 31, 2026, and collaboration revenue can shift sharply when milestones land.
What could go wrong
Tryngolza launch stalls
High impact · Medium oddsThe sHTG approval greatly expands Tryngolza's addressable market, but approval does not equal sales. Doctors need to adopt it, payers need to cover it, and patients need to start and stay on therapy. Ionis also expected a Q2 decline in Tringolza revenue tied to pricing changes before the larger launch.
Launch costs outrun revenue
High impact · Medium oddsIonis is building a larger commercial company while still funding research. Q1 2026 SG&A expense was $150.4 million, up from $76.3 million in Q1 2025. If new product sales do not ramp quickly, the path to cash flow breakeven by 2028 could slip.
Dawnzera gets squeezed in HAE
Medium impact · Medium oddsHereditary angioedema already has established treatments. Dawnzera's dosing profile may help, but patients and doctors may stay with known options. A slower launch would weaken the claim that Ionis can become a strong direct seller.
Partner and trial timing disappoints
High impact · Medium oddsIonis still relies on partners for royalties and milestone payments. Pelacarsen and WAINUA cardiovascular studies could add large future value if positive, but weak or delayed data would hurt sentiment and future revenue expectations.
Tariffs lift supply costs
Medium impact · Medium oddsIonis disclosed that tariffs of up to 100% on imported patented pharmaceutical products and active pharmaceutical ingredients were announced in April 2026, with specified exceptions. The company has not yet quantified the impact. This matters because Ionis is launching more products and making more commercial supply.
In one breath
What does Ionis Pharmaceuticals do?
Ionis makes RNA-targeted medicines, mainly antisense drugs. These drugs are designed to change how the body makes disease-related proteins.
Why does Tryngolza matter so much for Ionis?
Tryngolza is Ionis's first wholly owned medicine with a multibillion-dollar peak sales target from management. Its sHTG approval in June 2026 turns Ionis from a mainly royalty and R&D company into a bigger commercial execution story.
Is Ionis profitable?
Ionis is still in an investment phase. In Q1 2026, it reported a net loss of $92.5 million while spending heavily on product launches and research.
What should investors watch next?
The most important near-term items are Tryngolza sHTG launch sales, Dawnzera uptake, the September 22, 2026 FDA decision for zilganersen, and cardiovascular data from pelacarsen and WAINUA.